HLA class I expression, tumor escape and cancer progression

Current Cancer Therapy Reviews

Volumn 4, Issue 2, 2008, Pages 105-110

  Aptsiauri, Natalia ^a   Cabrera, Teresa ^a   Garcia Lora, Angel ^a   Ruiz Cabello, Francisco ^a   Garrido, Federico ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Cancer; HLA class I; Immune escape

Indexed keywords

EID: 54749148675     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339408784310052     Document Type: Review

References (61)

1. Miles AK, Matharoo-Ball B, Li G, Ahmad M, Rees RC. The identification of human tumour antigens Current status and future developments. Cancer Immunol Immunother 2006; (8): 996-1003.
2. Malyankar UM. Tumor-associated antigens and biomarkers in cancer and immune therapy. Int Rev Immunol 2007; 26(34): 223-247.
3. Basil CF, Zhao Y, Zavaglia K, et al. Common cancer biomarkers. Cancer Res 2006; 66(6): 2953-61.
4. Zinkernagel, RM, Doherty, PC. The discovery of MHC restriction. Immunol Today 1997; 18: 14-17.
5. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 1S3: 725-729.
6. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today 1993; 14: 491-499.
7. Seliger B, Cabrera T, Garrido F, Ferrone F. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002; 12: 3-13.
8. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours Immunol Today 1997
9. Knong HT, Restito NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3 (11): 999-1005.
10. Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 89-95.
11. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000; 191, 961-976.
12. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 2003; 52: 1-9.
13. Kageshita T, Ishihara T, Campoli M, Ferrone S. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 2005; 65: 419
14. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83: 117-158.
15. Cabrera T, Fernandez MA, Sierra A, et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996; 50: 127-134.
16. Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, Garrido F. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 2002; 51: 389-396.
17. Maleno I, Cabrera CM, Cabrera T, et al. Distribution of HLA class I altered phenotypes in colorectal carcinomas high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004; 56(4): 244-253.
18. Cabrera T, Pedrajas G, Cozar JM, et al. HLA class I expression in bladder carcinomas. Tissue Antigens 2003; 62: 324-327.
19. Maleno I, Romero JM, Cabrera T, et al. LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas. Immunogenetics 2006; 58: 503-510.
20. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F. MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 2007; 256: 139-189.
21. Rodriguez T, Aptsiauri N, Mendez R, Jimenez P, Ruiz-Cabello F, Garrido F. Different mechanisms can lead to the same altered HLA class I phenotype in tumors. Tissue Antigens 2007; 69 Suppl 1: 259-263.
22. Chen H L, Gabrilovich D, Tampe R, Girgis K R, Nadaf S, Carbone D P. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 1996; 13: 210-213.
23. Seliger B, Ritz U, Abele R, et al. Immune escape of melanoma first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001; 61(24): 8647-8650.
24. Koene GJ, Arts-Hilkes YH, van der Ven KJ, et al. High level of chromosome 15 aneuploidy in head and neck squamous cell carcinoma lesions identified by FISH analysis limited value of beta2-microglobulin LOH analysis. Tissue Antigens 2004; 64(4): 452-461.
25. Seliger B, Maeurer MJ, Ferrone & Antigen processing machinery breakdown and tumor growth. Immunol Today 2000; 21: 455-464.
26. Meissner M, Reichert TE, Kunkel M, et al. Defects in the human leukocyte antigen class I antigen-processing machinery in head and neck squamous cell carcinoma association with clinical outcome. Clin Cancer Res 2005; 11(7): 2552-2560.
27. Romero JM, Jimenez P, Cabrera T, et al. Coordinated downregulation of the antigen presentation machinery and HLA class I/ beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 2005; 113: 605.
28. Serrano A, Tanzarella S, Lionello I, et al. Reexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 2001; 94(2): 243-251.
29. Rodriguez T, Mendez R, Del Campo A, et al. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.BMC Cancer 2007; 23; 7: 34.
30. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting from immunosurveillance to tumor escape. Nat Immunol 2002; 11; 991-998
31. Zitvogel L, Tesmere A, Kroemer G. Cancer despite immunosurveillance immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715.
32. Chang CC, Ferrone S, Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 2007; 56(2): 227-36.
33. Malmberg KJ, Ljunggren HG. Escape from immune- and nonimmune-mediated tumor surveillance. Semin Cancer Biol 2006; 16(1): 16-31.
34. Whiteside TL. The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest 2007; 36(1): 25-46.
35. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65(8): 3044-3048.
36. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005; 437(7055): 141-146.
37. Real LM, Jimenez P, Kirklin A, et al. Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother 2001; 49(11): 621-628.
38. Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 2006; 118(1): 129-138.
39. Ljunggren H G, Karre K. In search of the 'missing self' MHC molecules and NK cell recognition. Immunol Today 1990; 11(7): 237-244.
40. Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunol Rev 2001; 181: 170-184.
41. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cbello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules implications for tumor immune escape. Cancer Immunol Immunother 2004; 53(10): 904-910.
42. Watson NF, Ramage JM, Madjd Z, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006; 118(1): 6-10.
43. Ruiz-Cabello F, Cabrera T, Lopez-Nevot MA, Garrido F. Impaired surface antigen presentation in tumors implications for T cell-based immunotherapy Semin Cancer Biol 2002; 12(1): 15-24.
44. Stewart TJ, Greeneltch KM, Lutsiak ME, Abrams SI. Immunological responses can have both pro- and antitumour effects implications for immunotherapy. Expert RevMolMed 2007; 9(4): 1-20.
45. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy possible mechanisms that influence tumor regression/progression.Cancer Immunol Immunother 2004 Oct; 53(10): 844-54.
46. Marincola F M, Jaffe E M, Hichklin D J, Ferrone, S. Escape of solid human tumors from T-cell recognition molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
47. Rivoltini L, Canese-P, Huber V, et al. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 2005; 5(4): 463-476.
48. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy moving beyond current vaccines. Nature Med 2004; 10: 909-915.
49. Cabrera T, Lara E, Romero JM, et al. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 2007; 56(5): 709-717.
50. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens immune surveillance and tumor escape. J Cell Physiol 2003; 195(3): 346-55.
51. Hicklin DL, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. beta2-Microglobulin mutations HLA class I antigen loss and tumor progression in melanoma. J Clin Invest 1998; 101(12): 2720-2729.
52. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immuno Immunother 2007; [Epub ahead of print].
53. Ogino T, Shigyo H, Ishii H, et al. HLA class I antigen downregulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006; 66(18): 9281-9289.
54. Kikuchi E, Yamazaki K Torigoe T, et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007; [Epub ahead of print].
55. Kitamura H, Honma I, Torigoe T, Asunuma H, Sato N, Tsukamoto T. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol 2007; 177(4): 1269-72.
56. Rolland P, Deen S, Scott I, Durrant L, Splendlove I. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res 2007; 13(12): 3591-3596.
57. Saio M, Teicher M, Cambell G, Feiner H, Delgado Y, Frey AB. Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma. Clin Exp Metastasis 2004; 21(3): 243-249.
58. Romero JM, Aptsiauri N, Vazquez F, et al. Analysis of the expression of HLA class I proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens 2006; 68(4): 303-310.
59. Madjd Z, Splendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005; 117(2): 248-255.
60. Menon AG, Morreau H, Tollenaar RA, et al. Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 2002; 82(12): 1725-1733.
61. Kloor M, Michel S, Buckowitz B, et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer. 2007; 121(2): 454-458.